Is I-Mab ADR (IMAB) Stock at the Top of the Biotechnology Industry?

I-Mab ADR (IMAB) is around the middle of the Biotechnology industry according to InvestorsObserver. IMAB received an overall rating of 36, which means that it scores higher than 36 percent of all stocks. I-Mab ADR also achieved a score of 34 in the Biotechnology industry, putting it above 34 percent of Biotechnology stocks. Biotechnology is ranked 69 out of the 148 industries.

IMAB has an Overall Score of 36. Find out what this means to you and get the rest of the rankings on IMAB!

See Full IMAB Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 36 means the stock is more attractive than 36 percent of stocks. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With I-Mab ADR Stock Today?

I-Mab ADR (IMAB) stock is down -1.49% while the S&P 500 has gained 0.25% as of 1:49 PM on Monday, Sep 18. IMAB is down -$0.02 from the previous closing price of $1.34 on volume of 728,516 shares. Over the past year the S&P 500 is up 14.40% while IMAB is down -73.60%. IMAB lost -$3.70 per share the over the last 12 months. Click Here to get the full Stock Report for I-Mab ADR stock.